JP2024538706A5 - - Google Patents

Info

Publication number
JP2024538706A5
JP2024538706A5 JP2024520924A JP2024520924A JP2024538706A5 JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5 JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5
Authority
JP
Japan
Application number
JP2024520924A
Other languages
Japanese (ja)
Other versions
JPWO2023060188A5 (https=
JP2024538706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077690 external-priority patent/WO2023060188A1/en
Publication of JP2024538706A publication Critical patent/JP2024538706A/ja
Publication of JPWO2023060188A5 publication Critical patent/JPWO2023060188A5/ja
Publication of JP2024538706A5 publication Critical patent/JP2024538706A5/ja
Pending legal-status Critical Current

Links

JP2024520924A 2021-10-08 2022-10-06 活性化可能サイトカイン構成体及び併用方法 Pending JP2024538706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163253893P 2021-10-08 2021-10-08
US63/253,893 2021-10-08
US202263328525P 2022-04-07 2022-04-07
US63/328,525 2022-04-07
PCT/US2022/077690 WO2023060188A1 (en) 2021-10-08 2022-10-06 Activatable cytokine constructs and combination methods

Publications (3)

Publication Number Publication Date
JP2024538706A JP2024538706A (ja) 2024-10-23
JPWO2023060188A5 JPWO2023060188A5 (https=) 2025-10-10
JP2024538706A5 true JP2024538706A5 (https=) 2025-10-10

Family

ID=84272320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520924A Pending JP2024538706A (ja) 2021-10-08 2022-10-06 活性化可能サイトカイン構成体及び併用方法

Country Status (10)

Country Link
US (2) US20230192798A1 (https=)
EP (1) EP4412635A1 (https=)
JP (1) JP2024538706A (https=)
KR (1) KR20240099172A (https=)
AU (1) AU2022360371A1 (https=)
CA (1) CA3233707A1 (https=)
IL (1) IL311972A (https=)
MX (1) MX2024004301A (https=)
TW (1) TW202334185A (https=)
WO (1) WO2023060188A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024353718A1 (en) * 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025195305A1 (en) * 2024-03-16 2025-09-25 Vibrant Pharma Limited Multispecific antigen binding proteins and uses thereof
CN120932734B (zh) * 2025-10-13 2026-01-30 良渚实验室 利用中介序列msa与扩散掩码机制的肽序列生成模型及生成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
RS59340B1 (sr) 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN111050803A (zh) * 2017-06-20 2020-04-21 德克萨斯大学系统董事会 用于治疗癌症的干扰素前药
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
BR112022009110A2 (pt) * 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
JP2024511387A (ja) * 2021-03-16 2024-03-13 シートムエックス セラピューティクス,インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法

Similar Documents

Publication Publication Date Title
JP2024538706A5 (https=)
CL2025002521A1 (es) Péptidos antifúngicos para el control de patógenos de plantas.
CL2026000108A1 (es) Estimuladores de defensa de plantas
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13156U (https=)
BY13169U (https=)
CN307044836S (https=)
CN307044271S (https=)
BY13137U (https=)
BY13157U (https=)
BY13141U (https=)
CN307044264S (https=)
CN307045776S (https=)
BY13142U (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
CN307046018S (https=)